GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Syneron Medical Ltd (NAS:ELOS) » Definitions » Return-on-Tangible-Equity

Syneron Medical (Syneron Medical) Return-on-Tangible-Equity : -10.71% (As of Mar. 2017)


View and export this data going back to 2004. Start your Free Trial

What is Syneron Medical Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Syneron Medical's annualized net income for the quarter that ended in Mar. 2017 was $-19.3 Mil. Syneron Medical's average shareholder tangible equity for the quarter that ended in Mar. 2017 was $180.4 Mil. Therefore, Syneron Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2017 was -10.71%.

The historical rank and industry rank for Syneron Medical's Return-on-Tangible-Equity or its related term are showing as below:

ELOS's Return-on-Tangible-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.87
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Syneron Medical Return-on-Tangible-Equity Historical Data

The historical data trend for Syneron Medical's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syneron Medical Return-on-Tangible-Equity Chart

Syneron Medical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.77 0.93 -2.81 -3.56 0.10

Syneron Medical Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.11 2.24 1.31 -1.99 -10.71

Competitive Comparison of Syneron Medical's Return-on-Tangible-Equity

For the Medical Devices subindustry, Syneron Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syneron Medical's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Syneron Medical's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Syneron Medical's Return-on-Tangible-Equity falls into.



Syneron Medical Return-on-Tangible-Equity Calculation

Syneron Medical's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2016 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2016 )  (A: Dec. 2015 )(A: Dec. 2016 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2016 )  (A: Dec. 2015 )(A: Dec. 2016 )
=0.179/( (175.077+180.646 )/ 2 )
=0.179/177.8615
=0.10 %

Syneron Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2017 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2017 )  (Q: Dec. 2016 )(Q: Mar. 2017 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2017 )  (Q: Dec. 2016 )(Q: Mar. 2017 )
=-19.316/( (180.646+180.146)/ 2 )
=-19.316/180.396
=-10.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2017) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Syneron Medical  (NAS:ELOS) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Syneron Medical Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Syneron Medical's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Syneron Medical (Syneron Medical) Business Description

Traded in Other Exchanges
N/A
Address
Syneron Medical Ltd., was incorporated in the State of Israel in July 2000. The Company completed its initial public offering of ordinary shares in August 2004. It designs, develops and markets aesthetic medical products based on its various technologies including its proprietary Electro-Optical Synergy, or ELOS, technology, which uses the synergy between electrical energy, including radiofrequency or RF energy, and optical energy to provide effective, safe and affordable aesthetic medical treatments. The Company's products, which it sells mainly to physicians and other practitioners, target non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin and laser-assisted lipolysis and topical skin brightening products.
Executives
North Tide Capital, Llc 10 percent owner 500 BOYLSTON STREET, SUITE 1860, BOSTON MA 02116
Laughlin Conan director, 10 percent owner C/O NORTH TIDE CAPITAL, LLC, 500 BOYLSTON STREET, SUITE 1860, BOSTON MA 02116
North Tide Capital Master, Lp 10 percent owner C/O NORTH TIDE CAPITAL, LLC, 500 BOYLSTON STREET, SUITE 1860, BOSTON MA 02116

Syneron Medical (Syneron Medical) Headlines